米吉珠单抗在炎症性肠病中的应用现状与展望
The Current Status and Prospects of the Application of Mirikizumab in Inflammatory Bowel Disease
DOI: 10.12677/acm.2024.1461810, PDF,   
作者: 马远寿：成都中医药大学临床医学院，四川 成都；李红燕, 刘世茹*：成都中医药大学附属医院肛肠科，四川 成都
关键词: 炎症性肠病；溃疡性结肠炎；克罗恩病；IL-23；米吉珠单抗；Inflammatory Bowel Disease； Ulcerative Colitis； Crohn’s Disease； IL-23； Mirikizumab
摘要: 炎症性肠病(inflammatory bowel disease, IBD)是一种免疫介导的慢性复发性疾病。治疗上以传统的抗肿瘤坏死因子(tumor necrosis factor, TNF)制剂为主，但随着药物的耐受性增加以及部分患者对抗TNF制剂无应答，越来越多的新型生物制剂问世并应用于IBD的治疗。白细胞介素(Interleukin, IL)-23是在炎症性肠病发病过程中起着重要作用的细胞因子。米吉珠单抗是针对IL-23的p19亚基的一种全人源单克隆抗体，在中重度IBD的治疗中显著改善患者临床症状，同时具有良好的耐受性和安全性。
Abstract: Inflammatory bowel disease (IBD) is an immune-mediated chronic recurrent disease. Traditional anti tumor necrosis factor (TNF) preparations are mainly used for treatment, but as drug tolerance increases and some patients have no response to TNF preparations, more and more new biological preparations are emerging and applied in the treatment of IBD. Interleukin (IL)-23 is a cytokine that plays an important role in the pathogenesis of inflammatory bowel disease. Mirikizumab is a fully human monoclonal antibody targeting the p19 subunit of IL-23. It significantly improves clinical symptoms in patients with moderate to severe IBD, while also exhibiting good tolerance and safety.
文章引用：马远寿, 李红燕, 刘世茹. 米吉珠单抗在炎症性肠病中的应用现状与展望[J]. 临床医学进展, 2024, 14(6): 557-561. https://doi.org/10.12677/acm.2024.1461810

参考文献

[1] Aniwan, S., Santiago, P., Loftus, E.V. and Park, S.H. (2022) The Epidemiology of Inflammatory Bowel Disease in Asia and Asian Immigrants to Western Countries. United European Gastroenterology Journal, 10, 1063-1076. [Google Scholar] [CrossRef] [PubMed]
[2] Park, J. and Cheon, J.H. (2021) Incidence and Prevalence of Inflammatory Bowel Disease across Asia. Yonsei Medical Journal, 62, 99-108. [Google Scholar] [CrossRef] [PubMed]
[3] Wils, P., Danese, S. and Peyrin-Biroulet, L. (2023) Promising Phase II Biologics for Future Crohn’s Disease Therapy. Expert Opinion on Investigational Drugs, 32, 495-507. [Google Scholar] [CrossRef] [PubMed]
[4] Pillay, L. and Subramanian, S. (2024) The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis. Inflammatory Bowel Diseases. [Google Scholar] [CrossRef] [PubMed]
[5] Keam, S.J. (2023) Mirikizumab: First Approval. Drugs, 83, 1045-1052. [Google Scholar] [CrossRef] [PubMed]
[6] Sakuraba, A., Sato, T., Kamada, N., Kitazume, M., Sugita, A. and Hibi, T. (2009) Th1/th17 Immune Response Is Induced by Mesenteric Lymph Node Dendritic Cells in Crohn’s Disease. Gastroenterology, 137, 1736-1745. [Google Scholar] [CrossRef] [PubMed]
[7] Fanizza, J., D’Amico, F., Lusetti, F., Fasulo, E., Allocca, M., Furfaro, F., et al. (2023) The Role of IL-23 Inhibitors in Crohn’s Disease. Journal of Clinical Medicine, 13, Article 224. [Google Scholar] [CrossRef] [PubMed]
[8] Geremia, A. and Jewell, D.P. (2012) The IL-23/IL-17 Pathway in Inflammatory Bowel Disease. Expert Review of Gastroenterology & Hepatology, 6, 223-237. [Google Scholar] [CrossRef] [PubMed]
[9] Wallace, K.L. (2014) Immunopathology of Inflammatory Bowel Disease. World Journal of Gastroenterology, 20, 6-21. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, S., Zhong, R., Tang, S., Chen, L. and Zhang, H. (2024) Metabolic Regulation of the Th17/Treg Balance in Inflammatory Bowel Disease. Pharmacological Research, 203, Article 107184. [Google Scholar] [CrossRef] [PubMed]
[11] Chen, L., Ruan, G., Cheng, Y., Yi, A., Chen, D. and Wei, Y. (2023) The Role of Th17 Cells in Inflammatory Bowel Disease and the Research Progress. Frontiers in Immunology, 13, Article 1055914. [Google Scholar] [CrossRef] [PubMed]
[12] Hanzel, J., Ma, C. and Jairath, V. (2023) Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis. Immunotherapy, 15, 1199-1208. [Google Scholar] [CrossRef] [PubMed]
[13] Steere, B., Beidler, C., Martin, A., Bright, S., Kikly, K. and Benschop, R.J. (2023) Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the P19 Subunit of Il-23. Journal of Pharmacology and Experimental Therapeutics, 387, 180-187. [Google Scholar] [CrossRef] [PubMed]
[14] Sandborn, W.J., Ferrante, M., Bhandari, B.R., Berliba, E., Feagan, B.G., Hibi, T., et al. (2020) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Ulcerative Colitis. Gastroenterology, 158, 537-549.E10. [Google Scholar] [CrossRef] [PubMed]
[15] D’Haens, G., Dubinsky, M., Kobayashi, T., Irving, P.M., Howaldt, S., Pokrotnieks, J., et al. (2023) Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 388, 2444-2455. [Google Scholar] [CrossRef] [PubMed]
[16] Sands, B.E., D’Haens, G., Clemow, D.B., et al. (2024) Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results from the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases.
[17] Sands, B.E., Peyrin-Biroulet, L., Kierkus, J., Higgins, P.D.R., Fischer, M., Jairath, V., et al. (2022) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn’s Disease. Gastroenterology, 162, 495-508. [Google Scholar] [CrossRef] [PubMed]
[18] Sandborn, W.J., Ferrante, M., Bhandari, B.R., et al. (2022) Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 20, 105-115.e14.

为你推荐